Divi's Laboratories faces a ₹570 crore draft tax assessment for FY23, citing Transfer Pricing and corporate tax adjustments.
Divi’s Laboratories has received a draft tax assessment order proposing ₹570.51 crore in additions to FY23 income due to transfer pricing and corporate tax adjustments, with potential tax liability ...
Join us on the Divis Labs Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock.
Discover the Divis Labs Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Divis Labs's latest details, including: Last ...
Reported Consolidated quarterly numbers for Divis Laboratories are: Net Sales at Rs 2,604.00 crore in December 2025 up 12.29% ...
Trade Brains on MSN
Can Divi's Labs generate $1 billion from GLP-1 projects by FY32?
India, March 12 -- Broking Jefferies is still optimistic about Divi's Laboratories and has stated that the company is set to ...
Divi’s Labs could emerge as a key beneficiary of the global GLP-1 drug boom, with new peptide manufacturing contracts and ...
Earnings call Divi's Laboratories reported Q3 FY26 revenue of ₹2,692 Cr, up 12.1% YoY, with profit before tax (ex-exceptional) rising 17.6% YoY to ₹854 Cr. Gross margin improved significantly due to ...
Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q2 2026 earnings on Nov 7, 2025. The consensus estimate for Q2 2026 revenue is $25.86 billion, and the earnings are expected to come in at ...
Hosted on MSN
Is 2026 a turning point for Divis Laboratories? Here's what Citi says about the pharma stock
India, Jan. 15 -- The shares of this pharma stock, engaged in the manufacturing and exporting of API's and Nutraceutical ingredients, are in focus after leading global brokerage, CITI, has expressed ...
Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25. Q2 growth was largely led by ...
HYDERABAD, India--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Divi’s Laboratories (NSE: DIVISLAB), one of the largest active ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results